Evogene director purchases 800,000 shares
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Evogene Ltd. director Leon Recanati purchased 800,000 Ordinary Shares on August 4, 2026 in multiple transactions at a weighted average price of $0.50 per share, increasing his direct ownership to 883,886 Ordinary Shares. He also reports existing stock option positions for informational purposes.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Ordinary Shares F1 | 800,000 | $0.50 | $400K |
| Holding | Stock Option (right to buy) F2 | -- | -- | -- |
| Holding | Stock Option (right to buy) F2 | -- | -- | -- |
| Holding | Stock Option (right to buy) F2 | -- | -- | -- |
| Holding | Stock Option (right to buy) F2 | -- | -- | -- |
| Holding | Stock Option (right to buy) F2 | -- | -- | -- |
| Holding | Stock Option (right to buy) F2 | -- | -- | -- |
| Holding | Stock Option (right to buy) F2 | -- | -- | -- |
| Holding | Stock Option (right to buy) F2 | -- | -- | -- |
| Holding | Stock Option (right to buy) F2 | -- | -- | -- |
| Holding | Stock Option (right to buy) F2 | -- | -- | -- |
| Holding | Stock Option (right to buy) F2, F3 | -- | -- | -- |
Footnotes (3)
- F1. The price reported in column 4 of this row is a weighted average price. These shares were purchased in multiple transactions on August 4, 2026 within a range of prices per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price.
- F2. There were no transactions effected in respect of the securities reported in this row, and the holdings in this row are being included for informational purposes only.
- F3. The options reported in this row vest equally on a quarterly basis (25% per quarter) such that they will be fully vested on the one-year anniversary of the August 18, 2025 grant date.
Key Figures
Key Terms
Stock Option (right to buy financial
weighted average price financial
grant date financial
vest equally on a quarterly basis financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
Does the Evogene (EVGN) insider report include any stock option holdings?
Was the Evogene (EVGN) insider purchase made under a Rule 10b5-1 trading plan?
What derivative exposure to Evogene (EVGN) does Leon Recanati report?
AI-generated analysis. How Rhea-AI works. Not financial advice.